Forge Therapeutics Excites Big Guns In Antibiotic World
Emerging Company Profile: Forge Therapeutics, which licensed intellectual property from the University of California San Diego in 2015...
Emerging Company Profile: Forge Therapeutics, which licensed intellectual property from the University of California San Diego in 2015...
In the pharmaceutical industry, the “batting average” for taking a compound from discovery to a marketed therapy leaves a lot to be desired.
Did you know that the greatest public transportation systems in the world have a direct and important connection to San Diego? The ticketing [...]
-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH [...]
The antibiotic pipeline is running dry. An analysis by the WHO of the development landscape for antibiotics aimed at the most dangerous bacterial [...]
San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and [...]
Less than a year after forming a strategic alliance to develop novel antibiotics against some drug-resistant superbugs, Forge Therapeutics and Evotec have expanded [...]
- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - Expansion Highlights Significance of US-UK Biotech Partnerships – [...]
Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum San Diego, California, October 11, 2017 – Forge Therapeutics, Inc., [...]